Cite
HARVARD Citation
Ngoi, N. et al. (2020). A multicenter phase II randomized trial of durvalumab (MEDI‐4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). International journal of gynecological cancer. 30 (8), p. . [Online].